Anemia is a major cause of morbidity in cancer patients resulting in poor physical performance, prognosis and therapy outcome. Initially, erythropoietin-stimulating agents (ESAs) were supposed to be the treatment of choice but about one third of patients turned out to be nonresponders and meta-analyses provided evidence of an increased risk of mortality if used excessively. This along with the successful use of intravenous iron for anemia in patients with chronic kidney disease prompted seven clinical studies evaluating the efficacy of intravenous iron as an adjunct to ESAs and four additional studies using intravenous iron only for anemia in cancer patients. These studies confirmed a superior response if ESAs are combined with intravenous iron and revealed iron only to be a useful option in patients with mild and absolute iron deficiency (AID). Currently, best treatment decisions for anemia in cancer might be based on measurements of serum ferritin (SF), transferrin saturation (TSAT), soluble transferrin receptor (sTfR), ferritin index (FI = sTfR/log SF), hypochromic reticulocytes (CHR) and C-reactive protein (CRP). However, there is still an urgent need for trials investigating diagnostic approaches to optimize therapy of anemia in cancer patients with iron and/or ESAs.
Introduction
Anemia is a major cause of morbidity in cancer patients [Barrett-Lee et al. 2005; Birgegard et al. 2006 ]. Low hemoglobin (Hb) levels in cancer patients were shown to correlate significantly with poor physical performance [Ludwig et al. 2004; Barrett-Lee et al. 2005; Birgegard et al. 2006; , prognosis and therapy outcome [Fein et al. 1995; Dubray et al. 1996; Glaser et al. 2001; Littlewood et al. 2001; Waters et al. 2002] . There are multiple causative factors including absolute iron deficiency (AID) which may result from chronic bleeding due to gastrointestinal or gynecological lesions, blood loss from surgery, nutritional deficiencies, anemia of chronic disease (ACD), myelosuppressive effects of chemotherapy or metastatic infiltration of the bone marrow limiting erythropoiesis [Rizzo et al. 2002; Grotto, 2008] . Even in the absence of overt anemia, iron deficiency is already associated with impaired physical function, weakness and fatigue which all abate upon iron therapy [Verdon et al. 2003; Brownlie et al. 2004] .
Anemia as major cause of morbidity in cancer took center stage with the approval of erythropoiesis-stimulating agents (ESAs) in 1997. At that time one did not think of functional iron deficiency (FID) in cancer patients yet and AID was generally considered of minor importance. Consequently, diagnostic procedures were not developed but therapy was initiated if three conditions were met: (1) diagnosis of cancer, (2) chemotherapy and (3) low Hb levels (< 10 g/dl). Accordingly, the first treatment guideline for cancer-associated anemia in 2002 was primarily a 'how to use ESA' guideline [Rizzo et al. 2002] . Only as the sixth of eight recommendations the guideline stated: 'Baseline and periodic monitoring of iron, total iron-binding capacity, transferrin saturation, or ferritin levels and instituting iron repletion when indicated may be valuable in limiting the need for epoetin, maximizing symptomatic improvement for patients, and determining the reason for failure to respond adequately to epoetin. There is inadequate evidence to specify the optimal timing, periodicity, or testing regimen for such monitoring'. The ESA-dominated view on anemia did not change with recent guideline revisions and diagnostic procedures of anemia have not been specified at all [Bokemeyer et al. 2007; Rizzo et al. 2010a Rizzo et al. , 2010b until the guidelines of the National Comprehensive Cancer Network (NCCN) [NCCN, 2012] . As a consequence, laboratory diagnostics are still hardly used prior to ESA therapy in daily practice [Ludwig et al. 2004; Mitchell, 2010; ]. Only about 50% of physicians make use of laboratory measurements and most use ferritin only.
Routine practice of triggering ESA treatment of cancer-related anemia based on chemotherapy and low Hb-values only [Steinmetz et al. 2008] has resulted in overall response rates of about 50-60% and the need for blood transfusion has remained high, at about 20-30%. Moreover, during recent years, evidence has been increasing that aggressive ESA treatment as well as blood transfusions may increase all-cause mortality [Spahn et al. 2008; Bohlius et al. 2009] although no such evidence is available if ESAs are used according to the label with target Hb levels between 11-12 g/dl [Glaspy et al. 2010] .
The poor response rates to ESA therapy alone and the positive experience with intravenous iron in chronic kidney disease prompted the first study of the combination treatment of ESAs and intravenous iron in cancer patients [Auerbach et al. 2004 ]. This was followed by six additional studies using iron as an adjunct to ESAs and by four studies using even iron alone in anemic cancer patients. In parallel, the understanding of the pathophysiology of cancer-related anemia has grown substantially [Grotto, 2008] and the detection of hepcidin opened new insights into the regulation of iron metabolism and hematopoiesis [Krause et al. 2000; Park et al. 2001; Goodnough et al. 2010; Thomas et al. 2011] . Consequently, the ACD which has already been known to cause anemia in cancer patients prior to the era of ESAs [Cash and Sears, 1989] came to the fore again [Weiss and Goodnough, 2005] whereas the effect of chemotherapy stood back. With the rediscovery of the concept of ACD the role of iron has changed too. While during the early ESA years iron was used in AID only, the FID described in ACD may explain benefits of iron also in patients with normal or even elevated total body iron. This review focuses on when and how to use iron in cancer-related anemia.
Pathophysiology of anemia in cancer and derived diagnostic tests
Based on WHO criteria [de Benoist et al. 2008] the definition of anemia is relatively simple: Hb <12 g/dl in nonpregnant women and Hb <13 g/ dl in male subjects older than 15 years. However, the problem of anemia in cancer is complex and it is not only challenging to identify causes in any given patient, but also to evaluate the relevance of single factors in general. If indicated by a careful anamnesis, initially bone marrow infiltration, hemolytic anemia, renal insufficiency and vitamin deficiency should be ruled out by bone marrow aspiration, measurement of serum levels of lactate dehydrogenase (LDH) and haptoglobin, of creatinine clearance and endogenous erythropoietin, and of vitamin B12 and folic acid, respectively ( Figure 1 ). However, the diagnosis of iron deficiency is not as easy, as one needs to discriminate AID and FID [NCCN, 2012] .
AID is a common cause of anemia in cancer patients, most often provoked by bleeding or iatrogenic blood loss, less frequently for dietary reasons. Low values of the erythrocyte indices major histocompatibility complex (MHC), mean corpuscular volume (MCV) and mean corpuscular hemoglobin concentration (MCHC) indicate diminished iron incorporation. Most often serum iron (Fe) is low in AID, but strongly varies with inflammatory reactions; moreover, it might be low in FID too. The most important parameter to assess whole body iron is serum ferritin (SF) which is the intracellular storage protein of iron; 1 µg/l SF corresponds to about 8-10 mg of iron stored. AID is defined as SF <30 µg/l and decreased saturation of serum transferrin (TSAT) <15% [NCCN, 2012] . Unfortunately, SF is an acute phase protein. Consequently during an inflammatory reaction, serum levels increase and there is no longer a clear-cut SF threshold indicating AID; however, SF levels <100 ng/ml make AID very likely and are therefore predictive of a good response to Fe iv, without using ESA [Auerbach et al. 2010; . Alternatively, intracellularly stored iron might be detected through staining of bone marrow smears which is not very practical though. However, the combination of SF, C-reactive protein (CRP), soluble transferrin receptor (sTfR), and low Hb-content of reticulocytes (Ret-Y, CHR) enables the detection of AID [Thomas and Thomas, 2002] even though SF levels might be >1000 µg/l [Steinmetz et al. 2010 ].
FID is a major contributor to ACD and accordingly also quite prevalent in cancer-associated anemia [Ludwig et al. 2011] . FID in cancer is most often provoked by tumor cells that interact with the immune system and by this cause a chronic state of inflammation along with the release of pro-inflammatory cytokines, such as interleukin-6 (IL-6) or tumor necrosis factor (TNF). In the clinical setting the extent of inflammation could be assessed through measurement of CRP, which is closely related to the serum IL-6 level. Cytokines foster the release of hepcidin, a peptide hormone and key regulator of iron homeostasis [Weiss and Goodnough, 2005] . Hepcidin blocks the membrane-tunnel protein ferroportin which normally transfers iron from the intracellular stores to transferrin, the transport protein in blood. Therefore, in the case of inflammatory reactions, increasing hepcidin levels lock iron in the cells; dietary iron is not released from the enterocytes in the small intestine, nor is storage iron released from the cells of the reticulo-endothelial system (e.g. macrophages, liver cells). As a consequence of the intracellular iron accumulation, the saturation of the iron transporting protein transferrin decreases. Therefore, despite high intracellular iron levels, a FID develops due to the restricted supply of iron to erythropoiesis (iron restricted erythropoiesis [IRE] ). NCCN guidelines define FID if TSAT is <20% along with normal or elevated SF levels up to 800 µg/l [NCCN, 2012] . During inflammation SF and hepcidin increase whereas transferrin decreases. As a consequence TSAT might be within the normal range and thus is not a good indicator for intravenous iron [Auerbach et al. 2010; ]. Hepcidin might be an alternative, but is unfortunately not yet available as a routine test [Goodnough et al. 2010; Thomas et al. 2011 ].
As iron is most important for the production of hemoglobin, IRE results in hypochromic anemia which is characterized initially by an increasing number of hypochromic reticulocytes (CHR, Ret-Y), and later by hypochromic erythrocytes (Hypo-Ery) [Brugnara, 2000; Thomas and Thomas, 2002; Goodnough et al. 2010 ]. In an Thomas and Thomas [2002] ). ESA: erythropoietin-stimulating agent; FID, functional iron deficiency; CRP, C-reactive protein; ACD, ane mia of chronic disease; AID, absolute iron deficiency; CHR, hypochromic reticulocytes. attempt to compensate for this anemia the quantity of erythropoietic precursor cells (erythroblasts and proerythroblasts) and the number of transferrin receptors on the surface of these precursor cells increase. The transferrin receptor is shed into the plasma where the sTfR concentration correlates with the surface amount. Thus, an elevated level of sTfR reflects an increased number of erythropoietic precursor cells and an increasing iron need for erythropoiesis [Cazzola and Beguin, 1992; Pettersson et al. 1994; Suominen et al. 2000; Beguin, 2002; Lee et al. 2002] . The value of sTfR alone for the differential diagnosis of anemia and for the prediction of treatment response is rather low [Steinmetz et al. 2007 ], but the ratio of sTfR and the logarithm of serum ferritin (sTfR/ log SF), the so-called ferritin index (FI), proved to discriminate FID and ACD [Punnonen et al. 1997 ]. However, cancer patients often have normal sTfR and FI despite a proven AID [Lee et al. 2002] . This may be explained by direct suppression of erythropoiesis through tumor cells and chemotherapy and a reduced production of endogenous erythropoeitin [Weiss and Goodnough, 2005] . The combination of the FI with the determination of hypochromic reticulocytes enables identification of patients with ACD, repleted iron stores (FI normal), but FID (CHR ≤28 pg) [Thomas and Thomas, 2002] .
Studies of iron as an adjunct to ESA for the treatment of anemia associated with chemotherapy
Approximately 30-50% of cancer patients with chemotherapy-related anemia do not respond to ESA alone and even in the remaining patients, response is often slow, not until 4-6 weeks after ESA initiation [Glaspy et al. 1997; Littlewood et al. 2001] . As response to ESA was shown to improve with intravenous iron supplementation in chronic kidney disease [Fishbane et al. 1995; Macdougall et al. 1996; Sepandj et al. 1996 ], Auerbach and colleagues performed the first randomized controlled-pilot trial testing combinations of ESAs and iron in cancer patients with chemotherapyrelated anemia [Auerbach et al. 2004] (Table 1) . Intravenous iron was superior to oral iron or ESA alone in increasing Hb and quality of life (QoL). Subsequently, five studies [Hedenus et al. 2007; Henry et al. 2007; Bastit et al. 2008; Pedrazzoli et al. 2008; Auerbach et al. 2010 ] confirmed a better response rate of intravenous iron along with ESAs as compared with ESA alone (Table 1) . In three studies using Epoetin alpha or beta, adjunct treatment with intravenous iron increased the Hb response rate (Δ +0.8 to 1.2 g/dl) from 36-53% to 68-93% versus ESAs alone [Auerbach et al. 2004; Hedenus et al. 2007; Henry et al. 2007 ], i.e. an improvement of 28-40%. In three studies using darbepoetin alpha, the response rate to ESA alone was slightly higher at 62-73%. The addition of intravenous iron improved these rates by about 10-15% to an overall response rate of 77-86%. Moreover, there was a quicker onset of response in four [Hedenus et al. 2007; Bastit et al. 2008; Pedrazzoli et al. 2008; Auerbach et al. 2010] and an improvement of QoL in two [Auerbach et al. 2004; Bastit et al. 2008] out of six studies. The rate of transfusions in the ESA alone and the combined ESA and oral iron groups varied significantly among the six studies from 3% to 30% and in one only study intravenous iron significantly reduced the rate from 26% to 16% [Bastit et al. 2008 ]. An ESA dose saving effect was demonstrated in another study [Hedenus et al. 2007] .
There was only one study that despite its large size failed to demonstrate significant clinical benefit of adjunct intravenous iron . A higher Hb response in the intravenous iron group was not significant, improvement of QoL was comparable and rates of transfusion were the same in all three study arms. Moreover, the study reported a higher rate of serious adverse events (SAEs) in the intravenous iron group as compared with the oral or no iron groups (55% versus 45% and 46%, respectively). Aapro and colleagues argued that the study might have failed due to the relatively low total (937.5 mg iron) and weekly iron dose (62.5 mg) and the high dropout rate due to which many patients did not receive the planned dose [Aapro et al. 2011] . Indeed, patients who received at least 750 mg of iron had a higher response rate than those who received less than 750 mg intravenous, oral or no iron (80% versus 56%, 67% and 65%, respectively) [Steensma, 2011] .
Studies using iron alone for treatment of anemia in cancer patients
The first study investigating intravenous iron alone in chemotherapy-associated anemia was performed in women with cervical cancer treated with chemoradiotherapy [Kim et al. 2007] (Table 2 ). The primary objective was to prevent exacerbation of anemia and to reduce the transfusion volume through intravenous iron sucrose. In the setting of this single-center [Dangsuwan and Manchana, 2010] . Again, this was a small study enrolling 22 patients per arm only, but intravenous iron resulted in a significant Hb increase of 0.9 g/dl and a significant reduction of the transfusion rate from 63.6% to 22.7%. While in both of these studies [Kim et al. 2007; Dangsuwan and Manchana, 2010] all patients received intravenous iron regardless of patients' actual iron status, in the German TANDEM trial patients were assigned to different treatment regimens based on the results of the diagnostic plot [Thomas and Thomas, 2002] . This diagnostic tool revealed in 207 (68%) out of 303 patients with a baseline ferritin ≥20 ng/ml no iron deficiency and were treated with ESAs alone. A total of 23 patients (8%) had ACD with FID and received ESA + intravenous iron, while 46 (15%) and 27 (9%) patients had mild and distinct AID, respectively, and received either oral or intravenous iron alone. Response rates were comparable in all groups, but the need for transfusions was slightly lower in groups receiving iron only [Steinmetz et al. 2010] (Table 1) .
The so far largest cohort of cancer patients treated for anemia with iron alone was in an observational study in Germany enrolling a total of 420 patients . Of these 347 (82.6%) received ferric carboxymaltose (FCM) as intravenous iron preparation only, the remaining 73 (17.3%) patients received FCM as an adjunct to ESA. About three out of four patients (74.3%) received cytotoxic chemotherapy concomitantly. At baseline, median Hb was 10.0 g/dl (95% confidence interval [CI] 9.1-10.6), ferritin was ≤100 ng/ml in 37.5%, and transferrin saturation <20% in 75.6% of patients. Average increase in Hb levels was 1.4 g/dL (median; 25%ile, 75%ile: 0.2, 2.3) in the overall population, 1.4 g/dl (0.3, 2.3) in patients censored for transfusions during the study, 1.4 g/dl (0.2, 2.3) in patients who received FCM only, and 1.6 g/dl (0.7, 2.4) in patients who received FCM plus ESA. The transfusion rate between week 5 and end of observation amounted to 7% and 11% of patients treated with FCM and FCM + ESA, respectively.
Safety of intravenous iron
There are many oral iron formulations, but in Europe only six different preparations are available for intravenous use (Table 3) . Most randomized studies (Tables 1 and 2) made use of iron natrium-gluconate-sucrose complex (in Europe: Ferrlecit®, Sanofi-Aventis) as an adjunct to ESAs. All but one of these studies showed similar rates of adverse events (AEs) in patients receiving ESAs alone, ESAs plus oral iron or ESAs plus intravenous iron. One study ] revealed a substantially higher rate of SAEs in the intravenous iron arm (darbepoetin plus ferric natrium-gluconate-sucrose complex). It was conjectured that these may be due to the three single doses of ferric-gluconate given concomitantly with ESAs, instead of two doses as per the drug label [Aapro et al. 2011 ]. However, sometimes life-threatening anaphylactic reactions as with older iron-dextran solutions have never been observed in cancer trials. In particular, the current high molecular weight sequestrants such as sucrose, isomaltosid and carboxymaltose have an excellent compatibility, not requiring a test dose at therapy initiation. In over 600 cancer patients treated with ferric carboxymaltose the rate of possibly or probably drug-related AEs, mainly nausea and diarrhea, were reported for 2.3% (n = 14) of patients only. Three SAEs comprised one death after a possibly related respiratory insufficiency in a 74-year-old man with advanced, pulmonary-metastasized head and neck cancer and two unlikely related cases of tachycardia and dyspnea. However, in none of the trials published so far has there been any signal for initially discussed serious adverse drug reactions that might occur with intravenous iron in cancer patients such as increased risk of infection, tumor progression and problems associated with an iatrogenic hemochromatosis, e.g. cardiovascular or thromboembolic events [Marx, 2002; Bailie et al. 2005; Chertow et al. 2006; Auerbach et al. 2007 ].
How should we manage anemia in cancer patients?
When and by which diagnostic parameters should we assess iron metabolism?
In patients being treated for cancer the cause of anemia should be investigated if Hb rapidly decreases by >2 g/dl or falls below 11 g/dl (Figure 1 ). Based on current practice guidelines (Table 4) at least SF and TSAT should be measured in addition to careful anamnesis. The assumption of FID should not be restricted to patients with SF <800-1000 ng/ml only, but additional parameters such as FI and hypochromic reticulocytes should be considered [Cazzola and Beguin, 1992; Pettersson et al. 1994; Suominen et al. 2000; Beguin, 2002; Lee et al. 2002; Thomas and Thomas, 2002] .
Which patients should be treated with iron?
Patients with AID should always be treated with iron. In patients with FID iron should be considered as an adjunct to ESAs (Figure 1 ). There is some evidence that the response to ESAs might Canadian guidelines [Mikhael et al. 2007] EORTC [Bokemeyer et al. 2007; Aapro and Link, 2008] ASH/ASCO [Rizzo et al. 2010 be enhanced even in patients not meeting the definition of AID and FID, e.g. patients with TSAT >15% and SF >10 ng/ml [Bastit et al. 2008] (Table 2) . The noninterventional study with ferric carboxymaltose described an effective intravenous iron-only therapy even in patients with SF >500 ng/ml ] (Table 2) . Moreover, patients without any evidence of FID at baseline may also develop FID under ESA therapy as indicated by an increase of sTfR and FI [Steinmetz et al. 2010] . There is still an urgent need for prospective trials optimizing anemia treatment based on baseline assessment and monitoring of iron status and erythropoiesis.
Should we treat patients with oral or intravenous iron?
Three studies prospectively tested oral versus intravenous iron and none showed a significant benefit of oral iron [Auerbach et al. 2004; Henry et al. 2007; Steensma et al. 2011 ]. This might be due to hindered oral intake during chemotherapy and of course due to the common inflammation reaction giving rise to the release of hepcidin preventing enterocytes from iron discharge into the circulation. In patients with AID without inflammation oral iron will be effective. On the other hand, intravenous iron always entails a quicker response and lacks the risk of incomplete absorption and of side effects such as gastrointestinal discomfort and constipation.
What is the optimal intravenous dose of iron?
In AID the need for iron might be calculated based on the formula of Ganzoni: However, this approach was used in one trial only [Auerbach et al. 2004] which was based on a modified formula calculated a need of 1000-3000 mg iron. The other studies combining ESAs with iron used a total dose between 750 and 2000 mg at a fixed dose schedule (Table 1) . Only in the first one [Auerbach et al. 2004 ] did a small group of patients (n = 41) receive the total dose as one infusion. The response was the same as in patients receiving the weekly schedule. One-week infusion intervals with single doses of 100-200 mg were used in five out of eight combined studies whereas in the remaining three studies there were 3-week intervals with single doses of 187-400 mg, corresponding to weekly doses of 62.5-133 mg. A weekly dose of 62.5 mg was discussed to be too low as the study failed to show a significant benefit of intravenous iron [Aapro et al. 2011; Steensma et al. 2011 ]. In the observational study with ferric carboxymaltose patients received iron only at single doses of 500 or 1000 mg and on average a total dose of 1000 mg (median). Thus, the total dose might be 1000 mg or more, but future dose optimization studies will be helpful.
Which intravenous preparation should be used?
Former reluctance in using intravenous iron was mostly driven by safety concerns, including life-threatening anaphylactic reactions. All of today's preparations show good or excellent tolerability (Table 3 ) and in particular macromolecular sequestrants such as carboxymaltose or isomaltosid allow for fast infusion of high total iron doses at low rates of side effects. Most experience in the cancer patient population is available for ferric carboxymaltose.
In summary, iron proved efficacious and effective for the treatment of cancer-associated anemia. Most studies confirmed an increased efficacy of the combination of ESAs with intravenous iron, but iron alone may be a useful option too. However, there is still an urgent need for trials investigating diagnostic approaches for the optimal tailoring of iron and/or ESA therapy in cancer patients with anemia.
